Prostate-specific Membrane Antigen PET in Prostate Cancer
Courtney Lawhn-Heath, Ali Salavati, Spencer C. Behr, Steven P. Rowe, Jérémie Calais, Wolfgang P. Fendler, Mattias Eiber, Louise Emmett, Michael S. Hofman, Thomas A. Hope
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.